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Medulloblastoma, the most common malignant brain tumor in children, occurs with
increased frequency in individuals with Fanconi anemia who have biallelic germline
mutations in BRCA2. We describe an 8-year-old child who had disseminated anaplastic 
medulloblastoma and a deleterious heterozygous BRCA2 6174delT germline mutation. 
Molecular profiling was consistent with Group 4 medulloblastoma. The posterior fossa 
mass was resected and the patient received intensive chemotherapy and craniospinal 
irradiation. Despite this, the patient succumbed to a second recurrence of his medullo-
blastoma, which presented 8 months after diagnosis as malignant pleural and peritoneal 
effusions. Continuous medulloblastoma cell lines were isolated from the original tumor 
(CHLA-01-MED) and the malignant pleural effusion (CHLA-01R-MED). Here, we provide 
their analyses, including in vitro and in vivo growth, drug sensitivity, comparative genomic 
hybridization, and next generation sequencing analysis. In addition to the BRCA2 
6174delT, the medulloblastoma cells had amplification of MYC, deletion at Xp11.2, and 
isochromosome 17, but no structural variations or overexpression of GFI1 or GFI1B. To 
our knowledge, this is the first pair of diagnosis/recurrence medulloblastoma cell lines, 
the only medulloblastoma cell lines with BRCA2 6174delT described to date, and the 
first reported case of a child with medulloblastoma associated with a germline BRCA2 
6174delT who did not also have Fanconi anemia.
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introduction
Medulloblastomas are the most common malignant brain tumors in children. While advances in 
diagnosis and therapy have improved long-term survival of children with standard-risk medul-
loblastoma, children with high-risk disease continue to fare poorly (1, 2). Grouping according 
to histology shows that patients with desmoplastic/nodular morphology have a better prognosis 
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than those with classic morphology, and both are better than 
medulloblastomas with large cell/anaplastic histology (3). More 
recent classifications, which divide medulloblastomas into four 
molecular subgroups [WNT, Sonic Hedgehog (SHH), Group 3 
and Group 4] show that tumors with genomic alterations in SHH 
and WNT signaling pathways overall had better prognosis than 
Groups 3 and 4 medulloblastomas (4–7).
BRCA2 (breast cancer 2, early onset), identified in 1994, is a 
tumor suppressor that functions in homologous recombination 
and double-stranded DNA repair (8, 9). Deleterious germline 
mutations in BRCA2 may confer up to 84% risk of breast cancer 
and 27% risk of ovarian cancer in women, and are frequently 
associated with Ashkenazi Jewish decent (Am. J. Hum. Genetics 
62:676–689, 1998) (10). The carrier rate of the BRCA2 6174delT 
founder mutation in individuals of Ashkenazi Jewish decent is 
estimated to be 0.9% (CI 0.6–1.5%), and is calculated to have 
arisen approximately 90 generations ago (11, 12). Over a decade 
ago, Howlett et al. reported that BRCA2 was the long sought-after 
gene mutated in the germline of patients with Fanconi anemia 
complementation group D1 (FANCD1) (13). Fanconi anemia 
is an autosomal recessive cancer susceptibility disorder caused 
by mutation in 1 of 13 known genes that function in genomic 
maintenance (13, 14). Children with Fanconi anemia who 
develop solid tumors, including medulloblastomas, frequently 
have biallelic germline mutations in BRCA2 (15–18). To date, 
however, there has been no report of a medulloblastoma associ-
ated with a deleterious BRCA2 germline mutation in a patient 
without Fanconi anemia.
Here, we report for the first time on a child carrying a familial 
heterozygous BRCA2 6174delT germline mutation, who pre-
sented with metastatic medulloblastoma. We also provide char-
acterization of his tumor and the unique pair of medulloblastoma 
cell lines generated from it at diagnosis and at the time of systemic 
metastatic recurrence.
Materials and Methods
cell culture
Primary tumor was obtained at initial surgery before any chemo-
therapy or irradiation. Recurrent tumor cells were obtained 
from a malignant pleural effusion that was removed for clinical 
indication at the time of second recurrence. Primary tumor tissue 
was minced and cultured in Dulbecco’s Modified Eagle Medium: 
Nutrient Mixture F-12 (DMEM/F-12) medium with B-27 sup-
plement (Invitrogen, CA, USA), EGF (20 ng/ml, Invitrogen, CA, 
USA), and bFGF (20 ng/ml, Cell Sciences, MA, USA) in a stand-
ard humidified incubator at 37°C in 5% CO2/95% atmospheric 
air. Gentamicin (50 μg/ml) was used for the initial 2  weeks of 
culture and then withdrawn to facilitate detection of mycoplasma. 
Tumor cells from the malignant pleural effusion were cultured 
similarly except without mincing. Small tandem repeat (STR) 
profile (ATCC) authenticated that both cell lines originated in 
the same individual. Both the original medulloblastoma cell line 
(CHLA-01-MED) and its subsequent pleural fluid recurrence 
cell line (CHLA-01R-MED) are now available through the ATCC 
repository (CRL–3021 and CRL-3034, respectively). Lysates from 
other cell lines were UW-228-2, D283MED medulloblastomas, 
CHLA-02-ATRT (ATCC CRL-3020) (19, 20), LN229 GBM, and 
293T cells.
chromosome analysis
BRCA2 mutation analysis was by PCR and direct DNA sequenc-
ing. Copy number analysis was performed on second passage cells 
from the tumor at diagnosis (CHLA-01-MED) and in recurrent 
tumor cells obtained directly from the malignant pleural effusion. 
DNAs were extracted using Qiagen micro kits (Qiagen Valencia, 
CA, USA). Concentrations and quality were determined by 
fluorometry (QuBit®, Life Technologies). Subsequently 1 μg of 
genomic DNA from each sample and a 1 μg aliquot of commercial 
46,XX reference template (Promega Madison, WI, USA) were 
digested with DNase I then labeled with Cy-5 dUTP and Cy-3 
dUTP respectively, using a BioPrime labeling kit (Invitrogen, 
Carlsbad, CA, USA). All labeling reactions were assessed using 
a Nanodrop assay (Nanodrop, Wilmington, DE, USA) prior to 
mixing and hybridization to comparative genomic hybridization 
(CGH) arrays with 400,000 oligonucleotide features (Agilent 
Technologies, Santa Clara, CA, USA). Microarray slides were 
scanned using an Agilent 2565C DNA microarray scanner 
and the images were analyzed with Agilent Feature Extraction 
software version 10.7 (FE 10.7) using default settings according 
to the supplier’s recommendations. Log2 ratios of fluorescent 
signals and corresponding log2 ratio errors were calculated from 
the log10 output of FE 10.7 for each hybridization and analyzed in 
GenomeWorkbench 7.0.
Genome-wide copy number determination for the diagnostic 
formalin-fixed paraffin embedded (FFPE) sample was carried 
out using OncoScan system utilizing molecular inversion probe 
(MIP) technology (Affymetrix, Santa Clara, CA, USA). In brief, 
three scrolls of FFPE material (20 μm thickness) were sent to 
Affymetrix for DNA extraction using the OncoScan FFPE assay 
kit and for generation of MIP probes followed by hybridization 
on the Affymetrix MIP 330K platform. The data were analyzed 
using APT tools and imported into OncoScan Nexus Express 
Software (Biodiscovery, El Segundo CA, USA) for visualization 
and analysis.
cytotoxicity assays
Cells were seeded in 150 μl Iscove’s Modified Dulbecco’s Medium 
(IMDM) supplemented with 20% fetal bovine serum, 4  mM 
l-glutamine, and 0.1% ITS stock solution (ITS is insulin, sele-
nium, and transferrin, Mediatech, VA, USA) at 12,000 cells/well 
in 96-well plates to facilitate attachment and spreading. After 6 h 
drugs were added at doses that are within clinically achievable 
plasma concentrations (21–23) and cells were incubated an addi-
tional 96 h. To measure cytotoxicity, fluorescein diacetate (FDA) 
and eosin Y (to quench background fluorescence) were added 
to cells at final concentration of 10 μg/ml, and incubated 30 min 
in the dark. Total fluorescence per well was measured using the 
DIMSCAN assay system, after digital thresholding, to further 
eliminate background fluorescence (24, 25). Results are expressed 
as survival fraction compared to control cells. The concentration 
of drug that was cytotoxic and/or growth inhibitory for 90% of 
cells (IC90) was calculated using the software “Calcusyn” (Biosoft, 
Cambridge, UK).
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informed consent
Following informed consent, the patient was enrolled on the 
Children’s Hospital Los Angeles Neural Tumors Registry, as 
approved by the institutional Committee for Clinical Investigations.
In vivo Tumor studies
Mouse studies were performed according to a protocol approved 
by the Children’s Hospital Los Angeles Institutional Animal Care 
and Use Committee. Intracranial implantation was done using 
a stereotaxic frame as previously described (26). Briefly, 2 × 105 
cells in 2 μl DMEM/F-12 were injected into the right caudate/
putamen to a depth of 3.3 mm in 4- to 6-week-old female NOD/
SCID mice (Bar Harbor, ME, USA). Mice were monitored daily 
and intracranial tumor size was followed by magnetic resonance 
imaging (MRI) at 1–3  weeks intervals. Mice were euthanized 
when the tumor reached a diameter of 4–5 mm or when the mice 
displayed signs of distress, whichever occurred earlier. Brains of 
the mice were harvested following vascular perfusion (PBS fol-
lowed by buffered 4% paraformaldehyde) under deep anesthesia. 
Half the brain, cut through the tumor, was snap frozen in OCT 
and the other half fixed in 4% buffered paraformaldehyde for 
paraffin embedding. Sections (6 μm) were cut and stained with 
hematoxylin and eosin (H&E).
Magnetic resonance imaging in mice was performed as 
described (26) using a 7-T Bruker Pharmascan scanner (Bruker, 
Ettlingen, Germany) with a 19  mm radiofrequency coil (27). 
About 15–20  min prior to scanning, mice were injected intra-
peritoneally with 100 μl gadopentatate dimeglumine (Magnevist, 
Bayer HealthCare Pharmaceuticals, Wayne, NJ, USA). Mice were 
then sedated with 5% isoflurane and held in an anesthetic plane 
with 1.5–2% for the entirety of the scans. Largest tumor axial 
dimensions were measured.
reagents
Cisplatin (CDDP, APP Pharmaceutical LLC, IL, USA), etoposide 
(ETOP, Bedford Laboratories, OH, USA), methotrexate (MTX, 
Hospira, IL, USA), and Vincritine (VCR, APP Pharmaceutical 
LLC, IL, USA) were obtained through the Children’s Hospital Los 
Angeles pharmacy. PARP inhibitor AZD2281 was from Selleck 
(Houston, TX, USA). FDA was from Eastman Kodak Company 
(Rochester, NY, USA). Eosin Y was from Sigma Chemical Co. 
(St. Louis, MO, USA). All other reagents were from Sigma unless 
specified otherwise.
rna Preparation and next generation 
sequencing and analysis
RNA was extracted from each sample of interest with the RNeasy 
minikit (Qiagen) according to established protocols. We used the 
NuGen Ovation RNASeq System v2 to generate double-stranded 
cDNA from 10–50 ng aliquots of RNA. These were subsequently 
amplified using NuGen’s SPIA linear amplification process. 
Amplified products were cleaned using Qiagen’s QIAquick PCR 
Purification Kit and quantitated using Invitrogen’s Quant-iT 
Picogreen. One microgram of amplified cDNA was fragmented on 
the Covaris E210 to a target size of 300 bp. Illumina’s TruSeq DNA 
Sample Preparation Kit was used to prepare libraries from 1 μg 
amplified cDNA according to the manufacturer’s protocol. Final 
libraries were quantitated by Qubit (Invitrogen) and evaluated on 
the Agilent Bioanalyzer. Libraries were clustered onto paired end 
flow cells at concentrations of 12–16 pM to generate total densi-
ties of 750,000–850,000/mm2 using the Illumina cBot and HiSeq 
Paired end cluster kit version 3. The flow cells were sequenced as 
83 × 2 paired end reads on the Illumina HiSeq using the TruSeq 
SBS sequencing kit version 3 and HiSeq control software version 
2.0.10 software. Bcl conversion was performed using Illumina’s 
Bclconverter software. All sequencing data were checked for 
quality using cycle-by-cycle quality plots. RNAseq data were 
aligned to human genome assembly GRCh37 (hg19, NCBI build 
37) using the STAR aligner (28). HTSeq was then used to further 
process the output from STAR aligner and format the data for 
DESeq, which was used to identify differentially expressed genes 
(29, 30). These genes were then mapped onto pathways using 
GeneGo. All array comparative genomic hybridization (aCGH) 
and expression data in this paper have been deposited at the 
National Center for Biotechnology Information Gene Expression 
Omnibus; accession number GSE70003.
Western Blot analysis
Cells were collected using cell scraper, re-suspended in 1× 
sodium dodecyl sulfate (SDS) sample buffer, sonicated, boiled 
for 5 min, and resolved by SDS–polyacrylamide gel electropho-
resis (SDS-PAGE) gel. Primary antibodies for western blots were 
anti-BRCA2, rabbit polyclonal (1:1,000; Cat# A303-434A-T, 
Bethyl Laboratories, TX, USA); anti-p21, goat polyclonal (1:500; 
Santa Cruz, CA, USA); anti-p53, mouse monoclonal (1:1000; 
BD Biosciences, CA, USA); anti-GAPDH, mouse monoclonal 
(1:20,000; Santa Cruz Biotechnology, CA, USA). Detection was 
by ECL (Amersham Biosciences, Piscataway, NJ, USA) and den-
sitometry was by ImageJ software (National Institutes of Health).
statistical analysis
Cell culture experiments were performed using at least three repli-
cates, except that DIMSCAN cytotoxicity assays used 12 replicates. 
Experiments were repeated three times unless indicated other-
wise. In vitro cytotoxicity data were analyzed and graphed using 
the DIMSCAN Data Analyzer Program and Prism GraphPad 4.0c. 
Results with a p-value <0.05 were considered significant.
results
Medulloblastoma in child with Familial 
heterozygous germline BRCA2 6174delT 
Mutation and Without Fanconi anemia
An 8–year-old previously healthy male of 97th percentile height, 
90th percentile weight and normal anatomy presented following a 
2-week history of worsening blurry vision, dizziness, and emesis, 
culminating in increasing somnolence. A brain MRI showed 
cerebellar mass with diffuse leptomeningeal enhancement con-
sistent with leptomeningeal metastases. The spine MRI showed 
disseminated leptomeningeal disease of the entire cord including 
the cauda equina region. The posterior fossa mass was completely 
resected. Due to persistent high cerebrospinal fluid (CSF) output 
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from the post-operative external ventricular drain in subsequent 
days, a ventriculoperitoneal shunt was placed. Lumbar CSF 
cytology showed 3,000 tumor cells per microliter. Pathological 
evaluation showed anaplastic medulloblastoma with myogenic 
differentiation (Figure  1). Molecular subgrouping was consist-
ent with Group 4 medulloblastomas using a medulloblastoma 
specific 31-gene TaqMan Low Density Array (TLDA) classifier 
(31). Chemotherapy was initiated according to the “Head Start” 
III protocol with vincristine, cisplatin, cyclophosphamide, 
etoposide, and high-dose methotrexate (32, 33). However, after 
two cycles, a new tumor nodule was apparent on a spine MRI 
and therapy was changed to craniospinal irradiation (36  Gy 
craniospinal, 18 Gy IMRT posterior fossa boost, and 9 Gy spinal 
cord boost) combined with concomitant daily carboplatin, with 
resultant shrinkage of the nodule. The child tolerated both the 
intensive chemotherapy and the craniospinal irradiation without 
FigUre 1 | Medulloblastoma with myogenic features. Posterior fossa 
anaplastic medulloblastoma with myogenic features. (a) MRI at diagnosis 
showing posterior fossa mass. (B) H&E stain showing anaplastic 
medulloblastoma. Note the large cells with pink cytoplasm. (c) BRCA2 
sequencing of peripheral blood mononuclear cells from the patient showed 
the wildtype nucleotide 6174T (c.5946T) on one allele (red peak), which is 
lost in the second allele, resulting in a G nucleotide (black peak) at the same 
position (arrow) and a downstream frameshift. (D) Immunohistochemistry 
demonstrating myogenic differentiation (cells positively staining for myogenin 
and desmin), as well as positive synaptophysin, and high mitotic index (Ki67).
unexpected or inordinate toxicities. Three months after the end 
of irradiation (8 months after diagnosis), the patient developed 
symptomatic malignant pleural and peritoneal effusions that 
reaccumulated repeatedly after drainage and led to his demise 
several weeks after their development.
The child’s family history was significant for maternal bilateral 
breast cancer developing at the age of 38 years, breast cancer in 
one of her two sisters, and colon cancer in their father. BRCA 
testing had previously demonstrated a deleterious heterozygous 
germline BRCA2 6174delT frameshift mutation in the mother 
and in her sister who had breast cancer. Family was non-Jewish 
Caucasians of European decent and they were not aware of 
Ashkenazi Jewish ancestors in recent generations. The patient’s 
peripheral blood mononuclear cells showed one wildtype BRCA2 
allele and BRCA2 6174delT on the other allele (Figure 1D). The 
family history, the patient’s prior normal medical history, his pre-
tumor normal blood counts and physical exam, his age at medul-
loblastoma diagnosis (8  years), normal tolerance to intensive 
chemotherapy, and normal diepoxybutane (DEB) chromosome 
breakage study did not support the presence of Fanconi anemia 
in this child.
new Paired Medulloblastoma cell lines: chla-
01-MeD and chla-01r-MeD
Two cell lines were established from the medulloblastoma of 
this patient: CHLA-01-MED from the primary tumor resected 
at diagnosis, and CHLA-01R-MED from tumor cells in the 
malignant pleural effusion 8  months later, after he was treated 
with chemotherapy (vincristine, cisplatin, cytoxan, etoposide, 
and methotrexate) followed by craniospinal irradiation with con-
comitant daily carboplatin. After securing low-passage cells, both 
cell lines, maintained in DMEM/F-12 medium supplemented 
with B-27 supplement, EGF (20 μg/ml) and bFGF (20 μg/ml), 
have been cultured continuously for more than 2 years and can 
thus be classified as permanent cell lines. Under these culture 
conditions, both CHLA-01-MED (Figure 2A) and CHLA-01R-
MED (Figure  2B) were non-adherent, formed loose spheres 
that were easily dispersed, and maintained 30–50% viability. 
Low-passage CHLA-01-MED (less than passage 10), when grown 
in IMDM with 20% FBS, attached to the tissue culture surface 
within 1  day. Single cells exited the sphere within a few days 
and grew as monolayer that rapidly proliferated (Figure  2C). 
However, after approximately 3 months, cells in these adherent 
FBS-containing cultures ceased to proliferate. With increasing 
passages, CHLA-01-MED required longer to attach and form 
a monolayer (Figure 2D) until they were no longer able to do 
so, even in FBS-containing culture conditions. The cell line from 
the malignant pleural effusion (CHLA-01R-MED) continuously 
grew in suspension even after months in IMDM/20% FBS, and 
was unable to grow as monolayer (data not shown). Low pas-
sages of both matched cell lines have been deposited in the ATCC 
repository (Manassas, VA, USA).
chla-01-MeD forms Tumors In vivo in Mice
Utility of tumor cell lines as pre-clinical models may be enhanced 
if they can grow into tumors in  vivo in mice. CHLA-01-MED 
FigUre 2 | chla-01-MeD and chla-01r-MeD medulloblastoma cell 
lines grow as neurospheres and form intracranial medulloblastoma 
in vivo. Cell lines shown were generated from the original tumor (CHLA-01-
MED) and the pleural effusion recurrence (CHLA-01R-MED). (a,B) The two 
cell lines grow as neurospheres when cultured under non-adherent 
serum-free conditions; (c,D) when seeded in FBS-containing medium, 
low-passage CHLA-01-MED attach and spread. (CHLA-01R-MED do not; 
not shown); (e,F) low-passage CHLA-01-MED injected into the frontal lobe 
of NOD/SCID mice developed tumors. (e) MRI of mouse brain with 
CHLA-01-MED tumor; (F) H&E of a CHLA-01-MED tumor. Right panel is 
inset from the 400× panel.
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cells (first passage of the cells from the resected tumor) injected 
intracranially into brains of NOD/SCID mice generated medul-
loblastomas, which were detected by MRI in four of the five mice 
tested starting 44  days after injection (Figure  2E, arrowhead). 
The morphology of these mouse tumors recapitulated the histol-
ogy of the patient’s tumor (Figure 2F), both were composed of 
densely packed primitive cells with round-to-oval hyperchro-
matic nuclei surrounded by scant cytoplasm and consistent with 
medulloblastoma.
chromosomal and array comparative genomic 
hybridization analysis of the Tumor and its cell 
lines
Karyotype analysis of CHLA-01-MED cells (cell line from original 
tumor at diagnosis) showed 42–46 chromosomes and two con-
sistent chromosomal rearrangements: der(17)t(1;17)(q11;q25) 
and der(18)(17;18)(q11.2;p11.2). Abnormalities of chromosome 
17 are common in both Group 3 and Group 4 medulloblastomas 
(6, 34–36). The CHLA-01R-MED cell line, generated from the 
malignant pleural effusion at recurrence, showed diploid cells 
with a del(11)(q13.3) in all examined cells. The 11q breakpoint 
in the recurrence cell line was also present in malignant cells 
analyzed directly from the pleural effusion, supporting its origin 
in the recurrent tumor rather than a product of cell culture. STR 
profile by ATCC (available on the ATCC website) confirmed that 
both lines originated in the same individual.
Genome copy number assessment of the FFPE tissue of this 
boy’s original tumor showed two significant events: amplification 
of the MYC locus and deletion at Xp11.2 (Figure 3).
Comparative genomic hybridization analysis of CHLA-01-
MED (passage 2 cells from the original tumor), of cells from the 
malignant pleural effusion itself, and of the cell line generated from 
this pleural effusion (CHLA-01R-MED, passage 12), identified 
copy number aberrations consistent with the FFPE findings and 
the karyotype of each (Figure 4). The most significant aberrant 
copy number interval was a focal (536 Mb) high-level (log2 ratio 
>8) amplification of MYC in both CHLA-01-MED and CHLA-
01R-MED (Figure 4B). Both diagnosis and recurrence cell lines 
from this boy’s medulloblastoma also showed the focal (88.8 kb) 
deletion at Xp11.2, which targeted the Synovial Sarcoma X 
breakpoint gene, SSX6 (Figure 4). Other significant alterations 
were duplication of the q arms of chromosomes 1 and 17 in 
CHLA-01-MED and deletion of 11q13.4-qtel with breakpoint 
at chromosome 11q13.4 targeting FCHSD2 (FCH and double 
SH3 domains protein 2) in CHLA-01R-MED (Figures 4A and 
5). RNASeq analysis confirmed that MYC was highly expressed 
in both cell lines. Interestingly, the long non-coding RNA Cancer 
Susceptibility Candidate 8 (CASC8), which is included within the 
focal MYC amplicon of both original and recurrent cell lines, 
was one of the most significant and differentially expressed 
transcripts with an approximately 700-fold overexpression in 
CHLA-01R-MED compared to the primary CHLA-01-MED cell 
line.
Chromosome 17q gain was not detected in the analysis of 
the FFPE diagnostic tumor material, although it was present in 
passage 2 cells in culture from this original tumor (CHLA-01-
MED cells) and in the pleural fluid cells obtained at the time of 
recurrence. This suggests that cells with 17q gain may have been 
a minority clone at diagnosis, which became rapidly prominent 
in culture and in the recurrence, or this difference may be due 
to differences in technique of analysis. The deletion in 11q, 
which was detected in the recurrence pleural effusion cells and 
their CHLA-01R-MED cell line but not in the cell line from the 
original tumor (CHLA-01-MED), was also not detected in the 
FFPE tissue from the original tumor, supporting that it originated 
in the recurrent tumor.
Northcott et al. recently showed that overexpression of GFI1 
or GFI1B, associated with genomic lesions (duplication, break-
points) around 1p22 and 9q34, respectively, act as oncogenes 
cooperating with MYC in Group 3 and Group 4 medulloblas-
tomas (38). CHLA-01-MED and CHLA-01R-MED showed no 
obvious copy number aberrations involving either gene. The 
RNAseq results also indicate that GFI1 was not highly expressed 
and GFI1B transcripts were not present at all, indicating that 
GFI1 and GFI1B were not the MYC-cooperating genes in this 
medulloblastoma.
Last, analysis of BRCA2 in CHLA-01-MED (second passage 
cells from the tumor at diagnosis) showed a BRCA2 6174delT 
frameshift mutation in one allele, similar to the BRCA2 6174delT 
germline mutation found in the germline of this patient and his 
mother. Western blotting of both cell lines showed a BRCA2-
reactive protein band of similar size to other cell lines, albeit at 
amounts that seem lower (Figure S1 in Supplementary Material), 
possibly consistent with expression from one allele only. This 
supports that protein was made in the brain from the remaining 
allele of BRCA2. Interestingly, the UW-228-2 medulloblastoma 
cell line showed almost no anti-BRCA2 antibody reactivity, 
while the other medulloblastoma cell line, D283MED, had 
BRCA2 protein amounts comparable to the CHLA-02-ATRT, 
FigUre 3 | Tumor specimen obtained at diagnosis has MYC 
amplification and deletion at Xp11.2. OncoScan results using MIP 
technology to detect copy number and loss of heterozygosity information of 
the original diagnostic tumor FFPE material demonstrates the amplified MYC 
locus at 8q24.21 (lower left panel) along with deletion of the SSX6 region at 
Xp11.2 (lower right panel). The deletion at Xp11.2 in this boy’s FFPE tumor 
sample, without detection of a non-deleted signal, suggests that the FFPE 
specimen analyzed comprised nearly 100% tumor cells, without significant 
contribution from non-tumor cells. This analysis does not show chromosome 
17 or 11q alterations (upper panel).
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LN229 GBM, and 293T cell lines (Figure S1 in Supplementary 
Material).
chla-01-MeD and chla-01r-MeD are 
resistant to commonly Used chemotherapy
We next examined the cytotoxicity profile of the new cell lines 
using drugs commonly used in medulloblastoma therapy: etopo-
side, vincristine, methotrexate, and cisplatin (22, 39), all of which 
had been used in this patient. Cytotoxicity assays showed resist-
ance of both CHLA-01-MED and CHLA-01R-MED to metho-
trexate, intermediate sensitivity to etoposide and vincristine, and 
better sensitivity to cisplatin (Figure  6; Table  1). The relative 
sensitivity to cisplatin may be associated with the BRCA2 muta-
tion in these cells, which has been reported to increase sensitivity 
to this drug (40). The recurrence cell line, CHLA-01R-MED, 
had approximately twofold decreased sensitivity to cisplatin 
(Figure 6; Table 1), possibly reflecting additional mutations (41). 
Because this medulloblastoma had an oncogenic mutation in 
BRCA2 (6174delT), we also tested its in vitro response to a PARP1 
inhibitor, thought to induce synthetic lethality in BRCA2-mutated 
breast cancer (42). However, both cell lines were resistant to the 
PARP inhibitor AZD2281 (up to 1 μM) and to its combination 
with etoposide (data not shown). In summary, this new pair of 
medulloblastoma cell lines is sensitive to cisplatin but resistant 
to vincristine, etoposide, methotrexate, and the PARP inhibitor, 
AZD2281.
chla-01-MeD and chla-01r-MeD have 
Functional p53
The activity of some chemotherapy drugs is linked to 
p53-dependent inhibition of proliferation or induction of 
apoptosis (21, 43). CGH analysis identified chromosome 17 
aberrations in both of our new medulloblastoma cell lines. These 
included duplication of 17q and an additional distinct breakpoint 
in CHLA-01R-MED (Figures 4A and 5B). CHLA-01R-MED also 
had a unique deletion at 17p13.2-ptel that included the TP53 
FigUre 4 | chla-01-MeD and chla-01r-MeD cell lines have MYC 
amplification and deletion at Xp11.2. Comparative genomic hybridization 
profiles of the cell lines generated from the original tumor (CHLA-01-MED) 
and the pleural effusion recurrence (CHLA-01R-MED). (a) Whole genome 
plots of CHLA-01-MED and CHLA-01R-MED. (B) High-level focal amplicon 
on chromosome 8q24.21 targets the MYC locus. Shaded areas denote copy 
number aberrations defined by ADM2 step gram algorithm (37). (c) 
CHLA-01-MED and CHLA-01R-MED show focal (88.8 kb) homozygous 
deletion at Xp11.2 targeting the Synovial Sarcoma X breakpoint gene SSX6 
(aCGH). Shaded areas and horizontal lines denote ADM2-defined copy 
number aberrant intervals. Results for both cell lines are displayed in each 
panel and highlight overlap of deleted region.
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locus. However, there were no mutations in the other copy of 
TP53. We examined the p53 functionality of these cell lines. At 
baseline, CHLA-01-MED and CHLA-01R-MED both expressed 
p53 protein (Figure 7A). Exposure to the DNA damaging agent 
etoposide (5  μg/ml) increased p53 protein expression in both 
cell lines as anticipated (Figures 7A,B). Etoposide also increased 
p21 protein, a downstream target of p53, indicating an intact 
sensing and response of the DNA damage-induced p53 pathway 
in both cell lines (Figure  7). Etoposide also induced apoptosis 
in CHLA-01-MED cells cultured in non-adherent (DMEM/F-
12 + B-27 + EGF + bFGF) as well as in adherent (IMDM + FBS) 
conditions (Figures  7D,E; measured as increased FITC-dUTP 
content). These data indicate that CHLA-01-MED and CHLA-
01R-MED have intact sensing and response of p53 and p21 to 
an etoposide signal, although they were only mildly responsive 
to it in cytotoxicity assays in Figure  6, suggesting a different 
mechanism for the drug resistance of this medulloblastoma.
Discussion
Medulloblastomas and other childhood cancers have been 
described in kindred with Fanconi anemia in the context of 
oncogenic BRCA2 germline mutations (15–18). Our patient 
did not have Fanconi anemia as assessed by lack of phenotypic 
stigmata, normal DEB chromosome breakage testing, and usual 
tolerance to craniospinal irradiation and intensive chemotherapy. 
The patient’s family history was also not suggestive of Fanconi 
anemia. Additionally, this child was different from children with 
Fanconi anemia and childhood cancer in that he was 8 years old 
at medulloblastoma presentation, whereas medulloblastomas in 
BRCA2-mutated Fanconi anemia patients typically present before 
age 5 years (18). Indeed, our patient’s germline BRCA2 6174delT 
was only on one allele, with the other BRCA2 allele remaining 
wildtype, whereas FANCD1 Fanconi anemia patients have bial-
lelic deleterious germline mutations in BRCA2. Additionally, the 
anti-BRCA2-reactive band on western blotting of the patient’s 
brain tumor-derived cells suggests that the brain had at least one 
intact BRCA2 gene. To our knowledge, this is the first reported 
child with medulloblastoma and a heterozygous germline BRCA2 
mutation and the first medulloblastoma described in the context 
of a BRCA2 deleterious mutation that is not in a patient with 
Fanconi anemia.
The BRCA2 6174delT mutation causes frameshift and 
premature truncation of the BRCA2 protein. It is a deleterious 
mutation that in its heterozygous germline state is associated 
with high incidence of breast and ovarian cancers (Am. J. Hum. 
Genetics 62:676–689, 1998) (10). This, together with involvement 
in medulloblastoma of genes that function in DNA stability and 
repair (44–48) and the critical role BRCA2 plays in neurogenesis 
and brain development (49, 50), renders it all the more interest-
ing that this is the first report of a medulloblastoma associated 
with a heterozygous (non-Fanconi anemia) deleterious BRCA2 
germline mutation. It is also interesting that one of the two other 
medulloblastoma cell lines tested (UW-228-2) had an only mini-
mal band reactive with the BRCA2 antibody on western blotting 
(Figure S1 in Supplementary Material), suggesting that BRCA2 
needs to be examined in more detail in additional samples of 
medulloblastoma, especially when associated with inactiva-
tion of TP53 (49, 51). In view of the high incidence of BRCA2 
6174delT carrier state in some populations (e.g., Ashkenazi Jews, 
~0.9%), it will also be important to examine if children from 
families carrying the heterozygous BRCA2 6174delT mutation 
have higher incidence of medulloblastoma than non-carriers.
The finding of chromosome 17q gain in passage 2 cultured 
cells from the original tumor, cells obtained directly from the 
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FigUre 5 | additional aberrations in chla-01-MeD and chla-01r-
MeD: (a) distinct chromosome 17 aberrations in chla-01-MeD and 
chla-01r-MeD: cgh results show a unique deletion of 17p13.2-ptel 
and a gain of 17q21.2-qtel in chla-01r-MeD (right and middle panels). 
In comparison, CHLA-01-MED had a gain of the entire q arm of chromosome 17 
(left panel). Shaded areas and horizontal lines in each panel denote ADM2-
defined copy number aberrant intervals. (B) CHLA-01R-MED, but not 
CHLA-01-MED, shows deletion of 11q13.4-qtel with breakpoint at chromosome 
11q13.4 targeting FCHSD2 (FCH and double SH3 domains protein 2) (aCGH). 
Shaded areas and horizontal lines in right and middle panels denote ADM2-
defined copy number aberrant intervals. In comparison, there were no copy 
number aberrations detected on chromosome 11 in CHLA-01-MED (left panel).
FigUre 6 | chla-01-MeD and chla-01r-MeD cells are resistant to 
chemotherapy agents commonly used in medulloblastoma therapy. 
Cells were incubated with drugs for 96 h and analyzed by DIMSCAN as 
described in the Section “Materials and Methods.” Each data point 
represents mean/SEM of 3 independent experiments, each performed in 12 
replicates. CDDP, cisplatin; ETOP, etoposide; MTX, methotrexate; VCR, 
vincristine.
TaBle 1 | ic90 of both medulloblastoma cell lines to commonly used 
chemotherapy in medulloblastoma.
ic90 etoposide 
(μg/ml)
Vincristine 
(ng/ml)
cisplatin 
(μg/ml)
Methotrexate  
(μg/ml)
CHLA-01-MED >10 >50 0.89 ± 0.17 >50
CHLA-01R-MED >10 >50 1.86 ± 0.67 >50
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malignant pleural effusion at recurrence, and the cell line grown 
from this pleural effusion, but not in the direct FFPE tumor sec-
tions from the original resection may be due to differences in 
the method of detection. Its presence in malignant cells directly 
obtained from the pleural effusion at recurrence makes it unlikely 
that this mutation was acquired during growth in culture. Most 
likely is that cells harboring the 17q gain were a subclone in the 
original tumor and thus, not detected in the FFPE sections from 
the biopsy material. Since 17q gain was detected already in pas-
sage 2 cells grown from the original tumor (CHLA-01-MED), this 
subclone likely had a survival advantage in culture conditions, 
allowing its growth into the cell line. Presence of 17q gain also in 
the pleural effusion recurrence cells prior to culture suggest that 
this subclone was resistant to the chemotherapy and irradiation 
and may have contributed to the recurrence. Absence of the dele-
tion in chromosome 11q in the FFPE tissue material is consistent 
with its absence in the CHLA-01-MED cell line from diagnosis. 
Its presence in the recurrence cells as well as in their cell line 
CHLA-01R-MED suggest that it became prominent during the 
evolution of the recurrence.
Isochromosome 17 is commonly seen in Group 3 and Group 
4 medulloblastomas (6, 34–36). CGH analysis identified chro-
mosome 17 aberrations with duplication of 17q in both original 
and recurrence cell lines. In the recurrence CHLA-01R-MED 
cell line, there were also an additional distinct breakpoint and 
a unique deletion at 17p13.2-ptel that includes the TP53 locus. 
However, we did not detect any mutations in TP53 nor were 
there any differences in p53 responses in our functional assays. 
Thus, the significance of these genomic lesions remains to be 
elucidated. High-level amplification of MYC was found in both 
cell lines. MYC elevation is more common in Group 3 medul-
loblastomas and is seen in up to 16.7% of them, but can also 
occur in some Group 4 or SHH tumors (52). Profiling of our 
patient’s medulloblastoma was consistent with Group 4. When 
MYC amplification occurs in a tumor with large cell/anaplastic 
histology and metastatic disease at diagnosis, the patients fare 
poorly, as did our patient (7, 53–55). Our combination of aCGH 
and RNASeq identified CASC8 as a co-amplified but differentially 
expressed gene in the CHLA-01R-MED line. While the role of 
this transcript is unclear in medulloblastoma, it is part of a cluster 
of related lncRNAs that map to the MYC locus and are implicated 
in cancer risk (56).
FigUre 7 | chla-01-MeD and chla-01r-MeD cells have functional 
p53. CHLA-01-MED and CHLA-01R-MED were incubated with 5 μg/ml 
etoposide for 24 h. Cells were analyzed by western blotting (a) and flow 
cytometry (D,e). (B,c) are densitometric analyses of (a). Results are mean/
SEM from two independent experiments.
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ing FCHSD2 (FCH and double SH3 domains protein 2) was only 
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or its cell line. To date, this gene has not been described in the 
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Interestingly, GeneGO analysis of all genes upregulated in the 
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acknowledgments
We are grateful to this child and his family for sharing tumor 
material and information, and thus contributing to the research 
efforts to understand and find cures for pediatric medulloblasto-
mas. We thank Mr. Filipp Gortalum for his expert technical assis-
tance in generation of these cell lines. This work was supported 
in part by grants from the Brad Kaminsky Foundation, Grayson’s 
Gift, Martell Foundation, the Michael Hoefflin Foundation, 
Nautica Malibu Triathlon, and the Rachel Ann Hage Foundation 
(AE-E) and by grant CA116201 from the National Institutes of 
Health (FC).
supplementary Material
The Supplementary Material for this article can be found online at 
http://journal.frontiersin.org/article/10.3389/fonc.2015.00191
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although at lower amounts than some other brain tumor cell lines. 
Western blot of whole cell lysates of the indicated cell lines was resolved by 
SDS-PAGE and hybridized with anti-BRCA2 antibody. GAPDH served as loading 
control. D283MED and UW-228-2 are medulloblastoma cell lines, CHLA-02-
ATRT is an ATRT cell line (20), and LN229 is a GBM cell line.
FigUre s2 | genego analysis based on rnas upregulated in chla-01r-
MeD relative to chla-01-MeD cells identified Wnt signaling as the most 
significant pathway.
TaBle s1 | genes and pathways differentially expressed between the 
diagnosis cell line chla-01-MeD and the chla-01r-MeD cell line from 
the pleural fluid recurrence. Differentially expressed genes and pathways were 
determined by combined RNA and aCGH analysis of the two cell lines, CHLA-
01-MED and CHLA-01R-MED.
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